レニン-アンジオテンシン系（RAS）作用薬の世界市場レポート 2025年

レニン-アンジオテンシン系（RAS）作用薬市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は5.8%で、77億3,000万米ドルに成長する見込みです。予測期間中の成長は、個別化治療への注目の高まり、合剤への需要の高まり、心血管調査への投資の拡大、新興市場におけるヘルスケアアクセスの拡大、生活習慣病の有病率の上昇など、いくつかの要因に起因すると考えられます。この期間の主な動向には、AIを活用した医薬品開発、ナノテクノロジーを活用したドラッグデリバリー、個別化医療の進展、安全な臨床データのためのブロックチェーンの活用、高血圧モニタリングのためのウェアラブルバイオセンサー、患者モデリングのためのデジタルツイン技術の応用などがあります。

高血圧の有病率の増加は、今後数年間におけるレニン-アンジオテンシン系（RAS）作用薬市場の拡大を促進すると予想されます。高血圧は、動脈壁に対する血液の力が常に高すぎる慢性疾患です。高血圧の増加は、不健康な食生活、特に塩分や加工食品の多い食生活が主な原因であり、これが血圧上昇や心血管系への負担増加の一因となっています。RAS作用薬は、血管を収縮させ、体液貯留を増加させるホルモンであるアンジオテンシンIIを阻害することによって血圧を調節し、高血圧を緩和するのに役立ちます。血管拡張を促進し、血圧を下げることで、これらの薬剤は高血圧症の管理に役立ちます。例えば、2024年10月にオーストラリア統計局が発表したところによると、2022年にはオーストラリア人の11.6％（300万人）が高血圧であり、男性（11.7％）と女性（11.6％）では同様の割合でした。このように、高血圧の有病率の上昇がRAS作用薬市場の成長を牽引しています。

RAS作用薬市場の主なプレーヤーは、有効性の改善、副作用の最小化、患者のコンプライアンス向上、高血圧、心不全、腎疾患への対処を目的として、アンジオテンシン変換酵素（ACE）阻害薬などの新規阻害薬の開発に注力しています。ACE阻害剤は、アンジオテンシンIを血管を狭める物質であるアンジオテンシンIIに変換する酵素を阻害することにより、血圧を下げる作用を持っています。例えば、2023年11月、英国の製薬会社Proveca Ltd.は、欧州委員会からアクメルディ（エナラプリルマレイン酸塩）口腔内分散錠の小児用医薬品製造販売承認（PUMA）を取得しました。アクメルディは、ACE阻害剤であり、アンジオテンシンIからアンジオテンシンIIへの変換を阻害することにより、血管を弛緩させ、血流を改善し、心臓の仕事量を減らすことにより、小児の心不全を治療します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界レニン-アンジオテンシン系（RAS）作用薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のレニン-アンジオテンシン系（RAS）作用薬市場：成長率分析
• 世界のレニン-アンジオテンシン系（RAS）作用薬市場の実績：規模と成長, 2019-2024
• 世界のレニン-アンジオテンシン系（RAS）作用薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界レニン-アンジオテンシン系（RAS）作用薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のレニン-アンジオテンシン系（RAS）作用薬市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アンジオテンシン変換酵素（ACE）阻害剤
• アンジオテンシンII受容体拮抗薬（ARB）
• レニン阻害剤
• アルドステロン拮抗薬
• その他の薬物クラス
• 世界のレニン-アンジオテンシン系（RAS）作用薬市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 高血圧
• 心不全
• 慢性腎臓病
• 糖尿病性腎症
• 冠動脈疾患
• 世界のレニン-アンジオテンシン系（RAS）作用薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 専門クリニック
• 世界のレニン-アンジオテンシン系（RAS）作用薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 調査機関
• 製薬会社
• その他のエンドユーザー
• 世界のレニン-アンジオテンシン系（RAS）作用薬市場アンジオテンシン変換酵素（ACE）阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• カプトプリル
• エナラプリル
• リシノプリル
• ラミプリル
• ペリンドプリル
• 世界のレニン-アンジオテンシン系（RAS）作用薬市場アンジオテンシンII受容体拮抗薬（ARB）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ロサルタン
• バルサルタン
• イルベサルタン
• オルメサルタン
• テルミサルタン
• 世界のレニン-アンジオテンシン系（RAS）作用薬市場レニン阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アリスキレン
• 世界のレニン-アンジオテンシン系（RAS）作用薬市場アルドステロン拮抗薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• スピロノラクトン
• エプレレノン
• 世界のレニン-アンジオテンシン系（RAS）作用薬市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アンジオテンシン受容体ネプリライシン二重阻害薬（ARNI）
• エンドセリン受容体拮抗薬
• 血管ペプチダーゼ阻害剤
• ミネラルコルチコイド受容体拮抗薬（MRA）
• アンジオテンシン受容体拮抗薬とネプリライシン阻害薬（ARNBI）

第7章 地域別・国別分析

• 世界のレニン-アンジオテンシン系（RAS）作用薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のレニン-アンジオテンシン系（RAS）作用薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• レニン-アンジオテンシン系（RAS）作用薬市場：競合情勢
• レニン-アンジオテンシン系（RAS）作用薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca plc
• Novartis AG
• GSK plc
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim GmbH
• Sandoz International GmbH
• Astellas Pharma Inc.
• Bausch Health Companies Inc.
• Aurobindo Pharma Limited
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Biocon Limited
• Daiichi Sankyo Company Limited
• Glenmark Pharmaceuticals Ltd.
• Torrent Pharmaceuticals Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• レニン-アンジオテンシン系（RAS）作用薬市場2029：新たな機会を提供する国
• レニン-アンジオテンシン系（RAS）作用薬市場2029：新たな機会を提供するセグメント
• レニン-アンジオテンシン系（RAS）作用薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Renin-angiotensin system (RAS)-acting agents are a group of medications designed to regulate blood pressure, fluid balance, and vascular resistance by targeting different components of the renin-angiotensin system, which plays a vital role in cardiovascular and renal function. These agents are frequently prescribed for conditions such as hypertension, heart failure, and chronic kidney disease, either by blocking the production of angiotensin II or inhibiting its effects on blood vessels.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary classes of drugs in the renin-angiotensin system (RAS)-acting agents include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), renin inhibitors, aldosterone antagonists, and others. ACE inhibitors are medications that block the enzyme responsible for converting angiotensin I into angiotensin II, a substance that narrows blood vessels and raises blood pressure. They are used for various indications such as hypertension, heart failure, chronic kidney disease, diabetic nephropathy, and coronary artery disease. These drugs are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and specialty clinics, catering to various end users, including hospitals, research institutes, pharmaceutical companies, and others.

The renin-angiotensin-system (RAS)-acting agents market research report is one of a series of new reports from The Business Research Company that provides renin-angiotensin-system (RAS)-acting agents market statistics, including renin-angiotensin-system (RAS)-acting agents industry global market size, regional shares, competitors with a renin-angiotensin-system (RAS)-acting agents market share, detailed renin-angiotensin-system (RAS)-acting agents market segments, market trends and opportunities, and any further data you may need to thrive in the renin-angiotensin-system (RAS)-acting agents industry. This renin-angiotensin-system (RAS)-acting agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The renin-angiotensin-system (RAS)-acting agents market size has grown strongly in recent years. It will grow from$5.82 billion in 2024 to $6.17 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth during the historic period can be attributed to several factors, including the rising prevalence of hypertension, the increasing incidence of cardiovascular diseases, the growing aging population, heightened awareness about blood pressure management, strong support from clinical research, and regulatory approvals for new drugs.

The renin-angiotensin-system (RAS)-acting agents market size is expected to see strong growth in the next few years. It will grow to$7.73 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth during the forecast period can be attributed to several factors, including an increasing focus on personalized treatment, higher demand for fixed-dose combinations, greater investment in cardiovascular research, expanding healthcare access in emerging markets, and the rising prevalence of lifestyle-related diseases. Key trends during this period include AI-driven drug development, nanotechnology-based drug delivery, advancements in personalized medicine, the use of blockchain for secure clinical data, wearable biosensors for hypertension monitoring, and the application of digital twin technology for patient modeling.

The growing prevalence of hypertension is expected to drive the expansion of the renin-angiotensin system (RAS)-acting agents market in the coming years. Hypertension, or high blood pressure, is a chronic condition in which the force of blood against the artery walls is consistently too high. The rise in hypertension is largely due to unhealthy diets, particularly those rich in salt and processed foods, which contribute to higher blood pressure and increased strain on the cardiovascular system. RAS-acting agents help mitigate hypertension by regulating blood pressure through the inhibition of angiotensin II, a hormone that constricts blood vessels and increases fluid retention. By promoting vasodilation and reducing blood pressure, these agents help manage hypertension. For example, in October 2024, the Australian Bureau of Statistics reported that 11.6% (3.0 million) of Australians had hypertension in 2022, with similar rates observed for males (11.7%) and females (11.6%). Thus, the rising prevalence of hypertension is driving the growth of the RAS-acting agents market.

Key players in the RAS-acting agents market are focusing on developing novel inhibitors, such as angiotensin-converting enzyme (ACE) inhibitors, to improve efficacy, minimize side effects, enhance patient compliance, and address hypertension, heart failure, and kidney diseases. ACE inhibitors work by lowering blood pressure through the blockage of the enzyme responsible for converting angiotensin I to angiotensin II, a substance that narrows blood vessels. For example, in November 2023, Proveca Ltd., a UK-based pharmaceutical company, received a grant from the European Commission for pediatric use marketing authorization (PUMA) for Aqumeldi (enalapril maleate) orodispersible tablets, which are indicated for the treatment of heart failure in children aged from birth to under 18 years. Aqumeldi, an ACE inhibitor, treats pediatric heart failure by preventing the conversion of angiotensin I to angiotensin II, thereby relaxing blood vessels, improving blood flow, and reducing the heart's workload.

In February 2023, AstraZeneca, a UK-based pharmaceutical company, acquired CinCor Pharma for $1.3 billion. Through this acquisition, AstraZeneca aims to strengthen its cardiorenal pipeline by adding CinCor's lead drug, baxdrostat (CIN-107), a selective aldosterone synthase inhibitor (ASI) designed to reduce blood pressure in treatment-resistant hypertension. CinCor Pharma, a U.S.-based biopharmaceutical company, is focused on developing RAS-acting agents, including baxdrostat, which targets resistant hypertension.

Major players in the renin-angiotensin-system (RAS)-acting agents market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sandoz International GmbH, Astellas Pharma Inc., Bausch Health Companies Inc., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Biocon Limited, Daiichi Sankyo Company Limited, Glenmark Pharmaceuticals Ltd., and Torrent Pharmaceuticals Ltd.

North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in renin-angiotensin system (RAS)-acting agents report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the renin-angiotensin system (RAS)-acting agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The renin-angiotensin system (RAS)-acting agents market consists of sales of enalapril, lisinopril, ramipril, and captopril. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Renin-Angiotensin-System (RAS)-Acting Agents Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on renin-angiotensin-system (ras)-acting agents market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for renin-angiotensin-system (ras)-acting agents ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The renin-angiotensin-system (ras)-acting agents market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors; Angiotensin II Receptor Blockers (ARBs); Renin Inhibitors; Aldosterone Antagonists; Other Drug Classes
• 2) By Indication: Hypertension; Heart Failure; Chronic Kidney Disease; Diabetic Nephropathy; Coronary Artery Disease
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Clinics
• 4) By End-User: Hospitals; Research Institutes; Pharmaceutical Companies; Other End-Users
• Subsegments:
• 1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril; Enalapril; Lisinopril; Ramipril; Perindopril
• 2) By Angiotensin II Receptor Blockers (ARBs): Losartan; Valsartan; Irbesartan; Olmesartan; Telmisartan
• 3) By Renin Inhibitors: Aliskiren
• 4) By Aldosterone Antagonists: Spironolactone; Eplerenone
• 5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs); Endothelin Receptor Antagonists; Vasopeptidase Inhibitors; Mineralocorticoid Receptor Antagonists (MRAs); Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)
• Companies Mentioned: Pfizer Inc.; Merck And Co. Inc.; Bayer AG; Sanofi S.A.; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Renin-Angiotensin-System (RAS)-Acting Agents Market Characteristics

3. Renin-Angiotensin-System (RAS)-Acting Agents Market Trends And Strategies

4. Renin-Angiotensin-System (RAS)-Acting Agents Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Renin-Angiotensin-System (RAS)-Acting Agents Growth Analysis And Strategic Analysis Framework

• 5.1. Global Renin-Angiotensin-System (RAS)-Acting Agents PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Renin-Angiotensin-System (RAS)-Acting Agents Market Growth Rate Analysis
• 5.4. Global Renin-Angiotensin-System (RAS)-Acting Agents Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Renin-Angiotensin-System (RAS)-Acting Agents Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Renin-Angiotensin-System (RAS)-Acting Agents Total Addressable Market (TAM)

6. Renin-Angiotensin-System (RAS)-Acting Agents Market Segmentation

• 6.1. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Angiotensin-Converting Enzyme (ACE) Inhibitors
• Angiotensin II Receptor Blockers (ARBs)
• Renin Inhibitors
• Aldosterone Antagonists
• Other Drug Classes
• 6.2. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hypertension
• Heart Failure
• Chronic Kidney Disease
• Diabetic Nephropathy
• Coronary Artery Disease
• 6.3. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Clinics
• 6.4. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Research Institutes
• Pharmaceutical Companies
• Other End-Users
• 6.5. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Captopril
• Enalapril
• Lisinopril
• Ramipril
• Perindopril
• 6.6. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Sub-Segmentation Of Angiotensin II Receptor Blockers (ARBs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Losartan
• Valsartan
• Irbesartan
• Olmesartan
• Telmisartan
• 6.7. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Sub-Segmentation Of Renin Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aliskiren
• 6.8. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Sub-Segmentation Of Aldosterone Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Spironolactone
• Eplerenone
• 6.9. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs)
• Endothelin Receptor Antagonists
• Vasopeptidase Inhibitors
• Mineralocorticoid Receptor Antagonists (MRAs)
• Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)

7. Renin-Angiotensin-System (RAS)-Acting Agents Market Regional And Country Analysis

• 7.1. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agents Market

• 8.1. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Renin-Angiotensin-System (RAS)-Acting Agents Market

• 9.1. China Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• 9.2. China Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Renin-Angiotensin-System (RAS)-Acting Agents Market

• 10.1. India Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Renin-Angiotensin-System (RAS)-Acting Agents Market

• 11.1. Japan Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• 11.2. Japan Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Renin-Angiotensin-System (RAS)-Acting Agents Market

• 12.1. Australia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Renin-Angiotensin-System (RAS)-Acting Agents Market

• 13.1. Indonesia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Renin-Angiotensin-System (RAS)-Acting Agents Market

• 14.1. South Korea Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• 14.2. South Korea Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Renin-Angiotensin-System (RAS)-Acting Agents Market

• 15.1. Western Europe Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• 15.2. Western Europe Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Renin-Angiotensin-System (RAS)-Acting Agents Market

• 16.1. UK Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Renin-Angiotensin-System (RAS)-Acting Agents Market

• 17.1. Germany Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Renin-Angiotensin-System (RAS)-Acting Agents Market

• 18.1. France Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Renin-Angiotensin-System (RAS)-Acting Agents Market

• 19.1. Italy Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Renin-Angiotensin-System (RAS)-Acting Agents Market

• 20.1. Spain Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Renin-Angiotensin-System (RAS)-Acting Agents Market

• 21.1. Eastern Europe Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• 21.2. Eastern Europe Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Renin-Angiotensin-System (RAS)-Acting Agents Market

• 22.1. Russia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Renin-Angiotensin-System (RAS)-Acting Agents Market

• 23.1. North America Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• 23.2. North America Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Renin-Angiotensin-System (RAS)-Acting Agents Market

• 24.1. USA Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• 24.2. USA Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Renin-Angiotensin-System (RAS)-Acting Agents Market

• 25.1. Canada Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• 25.2. Canada Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Renin-Angiotensin-System (RAS)-Acting Agents Market

• 26.1. South America Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• 26.2. South America Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Renin-Angiotensin-System (RAS)-Acting Agents Market

• 27.1. Brazil Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Renin-Angiotensin-System (RAS)-Acting Agents Market

• 28.1. Middle East Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• 28.2. Middle East Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Renin-Angiotensin-System (RAS)-Acting Agents Market

• 29.1. Africa Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
• 29.2. Africa Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Renin-Angiotensin-System (RAS)-Acting Agents Market Competitive Landscape And Company Profiles

• 30.1. Renin-Angiotensin-System (RAS)-Acting Agents Market Competitive Landscape
• 30.2. Renin-Angiotensin-System (RAS)-Acting Agents Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Renin-Angiotensin-System (RAS)-Acting Agents Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. Novartis AG
• 31.3. GSK plc
• 31.4. Teva Pharmaceutical Industries Ltd.
• 31.5. Boehringer Ingelheim GmbH
• 31.6. Sandoz International GmbH
• 31.7. Astellas Pharma Inc.
• 31.8. Bausch Health Companies Inc.
• 31.9. Aurobindo Pharma Limited
• 31.10. Cipla Limited
• 31.11. Dr. Reddy's Laboratories Ltd.
• 31.12. Biocon Limited
• 31.13. Daiichi Sankyo Company Limited
• 31.14. Glenmark Pharmaceuticals Ltd.
• 31.15. Torrent Pharmaceuticals Ltd.

32. Global Renin-Angiotensin-System (RAS)-Acting Agents Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Renin-Angiotensin-System (RAS)-Acting Agents Market

34. Recent Developments In The Renin-Angiotensin-System (RAS)-Acting Agents Market

35. Renin-Angiotensin-System (RAS)-Acting Agents Market High Potential Countries, Segments and Strategies

• 35.1 Renin-Angiotensin-System (RAS)-Acting Agents Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Renin-Angiotensin-System (RAS)-Acting Agents Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Renin-Angiotensin-System (RAS)-Acting Agents Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34948_Renin_Angiotensin_System_RAS_Acting_Agents_GMR_2025